A 2025 study using a commercial cannabis tracking app found that 111 self-identified autistic adults reported an average 73% reduction in symptom severity after inhaled cannabis use. However, the study had no control group, no blinding, and relied entirely on self-report, meaning the impressive-sounding numbers cannot be distinguished from placebo, expectancy, or natural symptom fluctuation. This is hypothesis-generating work, not proof of efficacy.

There are no FDA-approved treatments targeting the core features of autism spectrum disorder in adults, and conventional pharmacotherapy addresses only associated symptoms such as irritability or anxiety. Many autistic adults already use cannabis, often without clinical guidance, making the absence of rigorous evidence a genuine patient safety concern. This study is among the first to systematically capture real-world cannabis use data from autistic adults, and the question it raises is clinically pressing even if the answers it provides remain preliminary.

Autistic adults frequently report using cannabis to manage sensory overwhelm, repetitive thought patterns, emotional dysregulation, and social anxiety, yet the evidence base for these applications remains almost entirely anecdotal. The endocannabinoid system is implicated in several neurodevelopmental pathways relevant to ASD, and preclinical data suggest cannabinoids may modulate social behavior, anxiety, and sensory processing. Against this backdrop, researchers at the University of British Columbia used anonymized archival data from Strainprint, a Canadian cannabis tracking app, to examine acute symptom changes associated with inhaled cannabis in 111 self-identified autistic adults across 5,932 logged sessions. Users rated symptom severity on a 1 to 10 scale before and within four hours after each cannabis use event, with symptoms organized into four clusters: Sensory Sensitivity, Repetitive Behaviors, Mental Control, and Negative Affect.

The headline finding is a mean 73.09% reduction in overall symptom severity from pre-use to post-use ratings. Higher baseline severity consistently predicted larger reductions, and a dose-response pattern emerged for three of the four symptom clusters, with higher puff counts associated with greater relief from Repetitive Behaviors, Mental Control difficulties, and Negative Affect. Notably, the average dose did not increase across tracked sessions, which the authors interpret as evidence against tolerance-driven escalation. However, the study lacks any control group, placebo condition, or blinding, and ASD diagnosis was self-reported without clinical verification. The authors themselves describe this as a “first empirical examination” and call for randomized controlled trials. The apparent magnitude of benefit is striking but should be understood as a pre-post change in self-reported scores among motivated cannabis users, not as a controlled treatment effect.

I appreciate that this study exists. Autistic adults have been telling clinicians for years that cannabis helps them manage sensory overload, looping thoughts, and emotional flooding, and until now almost no one has tried to measure that systematically. The researchers made reasonable methodological choices within the constraints of app-based data, and the dose-response signal across three of four symptom clusters is genuinely interesting. But a 73% reduction reported by people who chose to use cannabis, tracked their own experience on a cannabis app, and knew exactly what they were consuming is not the same as a 73% treatment effect. Expectancy and regression to the mean could easily account for a large portion of that number.

In my practice, I see autistic patients who have found cannabis genuinely helpful, and I also see patients for whom it increases anxiety or worsens executive function. What I do is start low, go slow, document carefully, and adjust. I use this kind of study the way it should be used: as a signal that we are asking the right question, not as an answer. Until we have controlled trials, any clinician recommending cannabis specifically for ASD symptoms should be honest with patients about where the evidence actually stands.

This study sits at the very earliest stage of the research arc for cannabis in autism: real-world signal detection. It establishes that autistic adults are using cannabis for specific symptom clusters, that they perceive acute benefit, and that a dose-response relationship may exist for some symptoms. These are necessary precursors to clinical trial design but are not themselves clinical evidence. Clinicians should recognize that the absence of controlled data does not mean the absence of effect; rather, it means we cannot quantify or confirm the effect. The pattern observed here is consistent with what would be expected from both genuine pharmacological action and from unblinded self-assessment of a desired outcome.

From a safety standpoint, the finding that dose did not escalate over sessions is modestly reassuring but limited by the observational design and the possibility that users who did escalate simply stopped using the app. Cannabis, particularly high-THC products delivered via inhalation, carries known risks for anxiety exacerbation, psychomotor impairment, and in vulnerable populations, psychotic symptoms. Autistic adults often take concurrent medications including SSRIs, atypical antipsychotics, and anticonvulsants, all of which have potential interactions with cannabinoids via CYP450 enzyme pathways. Clinicians working with autistic

Physician-Led, Whole-Person Care

A doctor who takes the time to truly understand you.

Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness

One-on-One Cannabis Guidance

Metabolic Balance

Leave a Message
Metabolic Care
Medical Consulting
Cannabis Care